This clinical trial is focused on studying a condition known as Richter’s syndrome, which occurs when chronic lymphocytic leukemia (CLL) transforms into a more aggressive form of cancer called diffuse large B-cell lymphoma (DLBCL). The study aims to evaluate the effectiveness of a new treatment combination for patients who have not previously received treatment for Richter’s syndrome. The treatment involves a combination of medications, including Glofitamab, a bispecific antibody that targets specific proteins on cancer cells, in combination with either Rituximab or Obinutuzumab, along with a chemotherapy regimen known as CHOP. CHOP includes the drugs Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
The purpose of the study is to determine how well this combination of treatments works in reducing the cancer in patients with Richter’s syndrome. Participants in the study will receive up to six cycles of the treatment, which involves receiving the medications through an intravenous infusion, meaning the drugs are delivered directly into the bloodstream through a vein. The study will monitor the response of the cancer to the treatment over time, as well as any side effects that may occur.
Throughout the study, participants will undergo regular assessments to track the progress of the treatment. These assessments may include imaging tests and other evaluations to measure the size and activity of the cancer. The study will also look at how long the treatment effects last and the overall survival of the participants. The goal is to gather information that could lead to improved treatment options for patients with Richter’s syndrome in the future.
France 
